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EPA or fish oil supplementation has been suggested as treatments for the prevention of type 2 diabetes mellitus (T2DM) due to their lipid-lowering
and potential insulin-sensitising effects. We investigated the effects of supplementation with EPA (1 g/kg body weight per d) or fish oil (3 g/kg
body weight per d) on the age of onset of T2DM and circulating glucose, insulin, lipids, leptin and adiponectin in UC Davis (UCD)-T2DM
rats. Animals were divided into three groups starting at 1 month of age: control, EPA and fish oil. All the animals were followed until
diabetes onset or for up to 12 months of age. Monthly fasting blood samples were collected for the measurement of glucose, lipids, hormones
and C-reactive protein (CRP). Neither EPA nor fish oil delayed the onset of T2DM or altered fasting plasma glucose, insulin, CRP, adiponectin
or leptin concentrations. The groups did not differ in energy intake or body weight. Fish oil treatment lowered fasting plasma TAG concentrations
by 39 (SD 7) % (P,0·001) and EPA lowered fasting plasma NEFA concentrations by 23 (SD 5) % (P,0·05) at 4 months of age compared with the
control group. EPA and fish oil lowered fasting plasma cholesterol concentrations at 4 months of age by 19 (SD 4) and 22 (SD 4) % compared with
the control group, respectively (both P,0·01). In conclusion, EPA and fish oil supplementation lowers circulating lipid concentrations, but does
not delay the onset of T2DM in UCD-T2DM rats.
Diabetes prevention: EPA: Fish oil: TAG
Consumption of EPA and fish oil (consisting of EPA and
DHA) has been reported to reduce inflammation(1 – 5) and
improve cardiovascular risk factors(6 – 9), and possibly improve
insulin sensitivity(10,11). These effects suggest that chronic
supplementation with EPA and fish oil might potentially
delay or prevent the onset of type 2 diabetes mellitus (T2DM).
Many of the beneficial effects attributed to EPA and fish oil
intake, including the potential to improve insulin sensitivity,
appear to be related to a reduction of inflammation via two
main pathways. First, chronic consumption of fish oil and
EPA results in greater membrane phospholipid EPA content at
the expense of arachidonic acid(1). Arachidonic acid is the pre-
cursor to multiple inflammatory eicosanoid products, whereas
EPA is a poor substrate for eicosanoid production, and EPA-
derived eicosanoids are generally less bioactive(12). Secondly,
EPA has been shown to activate PPAR-mediated suppression
of NF-kB, a potent activator of inflammatory mediators(13 – 15).
Inflammation is believed to play a crucial role in the onset and
progression of T2DM, as expanding adipocytes secrete increas-
ing amounts of inflammatory mediators, such as IL-6 which
stimulates hepatic C-reactive protein (CRP) release, potentially
impairing insulin signalling(16,17).
In addition to their impact on inflammation, EPA and fish
oil consumption has been reported to lower circulating lipids
in rodents and human subjects(6,7,11,18). This action is
mediated in part by activation of PPAR-a (the pharmaceutical
target for fibrates) and g (the pharmaceutical target for
thiazolidinediones). Activation of PPAR-g by EPA and fish
oil-derived fatty acids has been shown to increase secretion
of the adipocyte hormone, adiponectin(3,5,11,19,20). Adiponectin
promotes improvement of insulin sensitivity and has
potential lipid-lowering effects, in part by activating adenosine
monophosphate-activated protein kinase and increasing fatty
acid oxidation(19). PPAR-g agonists may also act to lower
circulating lipids by expanding subcutaneous adipose depots
for fatty acid storage(21).
While the cardioprotective effects of marine-derived lipids
as nutritional supplements are becoming increasingly clear,
no studies have addressed the efficacy of EPA or fish oil in
the prevention T2DM. Some studies in rodent models have
* Corresponding author: P. J. Havel, fax þ1 530 752 4698, email pjhavel@ucdavis.edu
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demonstrated improved insulin sensitivity during fish oil
treatment(11,22); however, other studies in rodents(23,24) and
clinical studies in healthy subjects and patients with T2DM
have demonstrated that neither EPA nor fish oil improves
insulin sensitivity or lower plasma glucose(4,7,24 – 27).
Therefore, we sought to determine whether EPA or fish oil
can delay or prevent the onset of diabetes and/or lower
circulating lipids and markers of inflammation in UC Davis
(UCD)-T2DM rats, a rat model of T2DM with polygenic
adult-onset obesity and insulin resistance, and inadequate
b-cell compensation(28). Furthermore, we sought to determine
whether there are differences between the chronic effects
of EPA and fish oil supplementation by examining the
two treatment groups in parallel and providing the same
amount of n-3 fatty acids (as EPA or as EPA þ DHA) in
both groups.
Methods
Animals and diets
The UCD-T2DM rat model was produced by crossing obese
Sprague–Dawley rats prone to adult-onset obesity and insulin
resistance(29,30) with Zucker diabetic fatty lean rats that have
intact leptin signalling, but a defect in pancreatic b-cell insulin
gene transcription(31). This cross resulted in a new rat model
that develops polygenic adult-onset obesity and diabetes in
both sexes with rats exhibiting insulin resistance, impaired
glucose tolerance and eventual b-cell decompensation(28).
These rats develop diabetes when fed a standard low-fat
rodent chow diet and also demonstrate a later age of diabetes
onset than other rodent models of T2DM, such as the Zucker
diabetic fatty rat, making them highly suitable for diabetes
prevention studies(28,32).
Rats were housed in hanging wire cages in the animal
facility in the Department of Nutrition at the University of
California, Davis, and maintained on a 12 h light–dark
cycle. Food intake and body weight were measured three
times a week. Non-fasting blood glucose was monitored
every week with a glucose meter (One-Touch Ultra, LifeScan,
Milpitas, CA, USA) at 13.00–14.00 hours. Diabetes onset was
defined as a non-fasted blood glucose value above 11·1 mmol/l
(2000 mg/l) on two consecutive weeks(26). All rats were
followed until 1 year of age or for 4 months after the onset
of diabetes. The experimental protocols were approved by
the University of California, Davis Institutional Animal Care
and Use Committee.
Starting at 1 month of age, male animals were divided into
three groups: control (n 20), EPA (n 15) and fish oil (n 17).
Purified ethyl-all-cis-5,8,11,14,17-icosapentaenoate (Mochida
Pharmaceutical Company, Shizuoka, Japan) or fish oil
(18 % EPA, 12 % DHA; Jedwards, Quincy, MA, USA) was
mixed with ground rodent chow (no. 5012; PMI Nutrition
International LLC, Brentwood, MO, USA) to provide a
dose of 1 g EPA/kg body weight per d or 3 g fish oil/kg
body weight per d. In order to provide the specified per kg
body weight dose, the amount of EPA or fish oil in the
diet was gradually increased until 4 months of age,
the time at which the animals had reached a relatively
stable adult body weight. At 4 months of age, the EPA-
supplemented diet contained 21 mg EPA/g of diet, and the
fish oil-supplemented diet contained 13 mg EPA plus
8 mg DHA/g of diet. All the diets were supplemented with
safflower oil to equalise the fat content of the three diets.
The percentage energy from fat, protein and carbohydrate
was 27, 23 and 50 %, respectively. The fatty acid composition
of the diet is shown in Table 1. Baseline body weights in all
the groups were 110 (SD 2) g. Blood samples were collected
from the tail after a 12 h fast each month up to 8 months of
age for the measurement of glucose, insulin, TAG, NEFA,
total cholesterol, adiponectin and leptin. Plasma CRP was
measured at baseline and at 4 months of age.
Assays
Plasma glucose and cholesterol were measured using
enzymatic colorimetric assays (Thermo DMA Louisville,
CO, USA). Plasma TAG and NEFA were measured using
enzymatic colorimetric assays (L-type TG H kit, NEFA
Microtiter C kit; Wako Chemicals, Inc., Richmond, VA,
USA). Plasma insulin, leptin and adiponectin were measured
using rodent/rat-specific RIA (Millipore, St Charles, MO,
USA). Plasma CRP was measured using ELISA (BD
Biosciences, San Jose, CA, USA).
Statistics and data analysis
Data are presented as means with their standard errors.
Statistical analyses were performed using GraphPad Prism
4.00 for Windows (GraphPad Software, San Diego, CA, USA).
Table 1. Experimental diet composition
Control EPA Fish oil
Energy content (kJ/g diet) 14·6 14·6 14·6
Safflower oil (g/kg diet) 65 45 –
EPA (g/kg diet) – 20 –
Fish oil (g/kg diet) – – 65
Crude fat (g/kg diet) 117 117 117
Fatty acid (% of total fatty acids)
12 : 0 (Lauric) 0·00 0·00 0·08
14 : 0 (Myristic) 0·46 0·46 4·82
15 : 0 (Pentadecanoic) 0·00 0·00 0·32
16 : 0 (Palmitic) 10·09 9·01 16·33
16 : 1 (Palmitoleic, n-7) 0·61 0·61 5·57
17 : 0 (Heptadecanoic) 0·00 0·00 0·27
18 : 0 (Stearic) 3·06 2·62 3·58
18 : 1 (Oleic, n-9) 17·59 15·11 16·26
18 : 2 (Linoleic, n-6) 62·49 50·32 22·65
18 : 3 (g Linolenic, n-6) 0·00 0·00 0·17
18 : 3 (Linolenic, n-3) 2·42 2·42 2·89
18 : 4 (Octadecatetraenoic, n-3) 0·09 0·09 2·02
20 : 0 (Arachidic) 0·15 0·15 0·33
20 : 1 (Eicosenoic, n-9) 0·15 0·15 0·97
20 : 2 (Eicosadienoic, n-6) 0·04 0·04 0·17
20 : 4 (Arachidonic, n-6) 0·07 0·07 0·72
20 : 3 (Eicosatrienoic, n-3) 0·00 0·00 0·09
20 : 5 (EPA, n-3) 0·59 17·95 11·09
22 : 0 (Behenic) 0·23 0·20 0·25
22 : 1 (Erucic, n-9) 0·00 0·00 0·18
22 : 5 (Docosapentaenoic, n-6) 0·11 0·11 1·41
24 : 0 (Lignoceric) 0·10 0·10 0·10
22 : 6 (DHA, n-3) 0·48 0·48 7·11
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Diabetes onset was analysed by log-rank testing of
Kaplan–Meier survival curves up to 10 months of age.
Longitudinal data were compared by two-factor repeated-
measures ANOVA (time and treatment) followed by post
hoc analysis with Bonferroni’s multiple comparison test.
One-factor ANOVA was used to analyse data assessed at a
single time point. One animal from the control group and
one animal from the fish oil-supplemented group became
diabetic at too early an age to allow collection of blood
samples up to 8 months of age and therefore were included
in incidence analysis, but not in the longitudinal analyses.
Differences were considered significant at P,0·05.
Results
Effect of EPA and fish oil supplementation on type 2 diabetes
mellitus onset, body weight and energy intake
There were no significant differences in the age of onset of
diabetes or diabetes incidence between the three treatment
groups (Fig. 1). Average ages of diabetes onset up to
1 year of age were 6·7 (SD 0·6), 6·0 (SD 0·6) and 6·0
(SD 0·8) months in the control, EPA-treated and fish oil-treated
groups, respectively. Diabetes incidence was 85, 87 and
88 % in the control, EPA-treated and fish oil-treated groups,
respectively. Energy intake did not differ significantly
between treatment groups in the first 5 months of treatment
(Fig. 2(a)). Starting at 6 months of age, fish oil-treated
animals were consuming somewhat more energy than
control animals (P,0·05). However, when prediabetic and
diabetic animals were analysed separately, the average
energy intake between 6 and 7 months of age did not differ
among groups, and all diabetic animals consumed significantly
more energy than prediabetic animals (P,0·001) (Fig. 2(b)).
At 6 months of age, 56 % of fish oil-treated animals were
diabetic, whereas 26 % of control animals were diabetic.
Previously reported data demonstrate that UCD-T2DM rats
develop progressive glucosuria and decreases in the
circulating insulin and leptin concentrations after diabetes
onset(28). Thus, following T2DM onset, animals increased
their food intake to compensate for the energy lost from
glucosuria, an effect that is probably mediated by the
decreases in insulin and leptin(28). There were no differences
in body weight between treatment groups (Fig. 2(c)).
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Fig. 1. Kaplan–Meier analysis of diabetes incidence in control (n 20),
EPA-supplemented (n 15) and fish oil (FO)-supplemented (n 17) animals.
Values were not significant by log-rank testing of Kaplan–Meier curves.
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Fig. 2. Energy intake (metabolisable energy) (a) and body weight (c) in
control (n 19), EPA-supplemented (n 15) and fish oil (FO)-supplemented
(n 16) animals. ††† Mean values were compared using two-factor (time and
treatment) repeated-measures ANOVA (P,0·001). * Mean values were
significantly different when compared with fish oil by Bonferroni’s post test
(P,0·05). Average energy intake (b) between 6 and 7 months of age in
prediabetic control (n 13), EPA-supplemented (n 5) and fish oil-supplemented
(n 6) animals, and diabetic control (n 6), EPA-supplemented (n 10) and fish
oil-supplemented (n 10) animals. ††† Mean values were compared using
one-factor ANOVA (P,0·0001). *** Mean values were significantly different
when compared with values in prediabetic animals by Bonferroni’s post test
(P,0·001). –W–, Control; –X–, EPA; K, FO.
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Effect of EPA and fish oil supplementation on fasting plasma
glucose, lipids, hormones and C-reactive protein
Fasting plasma glucose concentrations did not differ between
groups (Fig. 3(a)). However, fasting plasma glucose concen-
trations tended to increase in the fish oil–supplemented and
EPA-supplemented groups starting at 7 months of age. This
trend was due to the higher incidence of diabetes in the fish
oil-treated and EPA-treated groups compared with the control
group. At 7 months of age, 37 % of control animals were
diabetic, whereas 67 and 56 % of EPA-supplemented and
fish oil-supplemented animals were diabetic, respectively.
Fasting plasma insulin concentrations did not differ between
groups; however, animals supplemented with fish oil tended
to have lower fasting plasma insulin concentrations than
control animals after 4 months of treatment (Fig. 3(b)).
Fish oil supplementation lowered fasting plasma TAG con-
centrations compared with control (239 (SD 7) % at 4 months
of age) (Fig. 4(a)). Overall, EPA supplementation did not sig-
nificantly lower fasting plasma TAG concentrations compared
with control animals. However, EPA supplementation lowered
fasting plasma TAG concentrations in diabetic animals (245
(SD 3) %) at 4 months of age compared with 4-month-old dia-
betic control animals (P,0·001, control: n 4, fish oil: n 6).
EPA supplementation lowered fasting plasma NEFA concen-
trations by 23 (SD 5) % compared with control at 4 months of
age (P,0·05) (Fig. 4(b)). Fish oil supplementation significantly
lowered fasting plasma cholesterol concentrations throughout
the sampling period (222 (SD 4) % at 4 months of age)
(Fig. 4(c)). EPA supplementation also lowered fasting plasma
cholesterol concentrations (219 (SD 4) % at 4 months of age).
Fasting plasma adiponectin and leptin concentrations did
not differ between groups over the course of the study
(Fig. 5(a) and (b)). Fasting plasma CRP concentrations did
not differ between groups at 4 months of age (Table 2).
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Fig. 3. Fasting plasma glucose (a) and insulin (b) concentrations in control
(n 19), EPA-supplemented (n 15) and fish oil (FO)-supplemented (n 16)
animals. –W– Control; –X–, EPA; K, FO.
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Fig. 4. Fasting plasma TAG (a), NEFA (b) and cholesterol (c) concentrations
in control (n 19), EPA-supplemented (n 15) and fish oil (FO)-supplemented
(n 16) animals. Mean values were significantly different by two-factor
ANOVA: †P,0·05, ††P,0·01, †††P,0·001. Mean values were significantly
different from those of the control group by Bonferroni’s post test: *P,0·05,
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Discussion
Previous studies investigating the effects of EPA and fish oil
have demonstrated the anti-inflammatory(1,33) and cardiopro-
tective properties for these supplements(6 – 9). However, evi-
dence that fish oil or EPA increases insulin sensitivity and
improves glucose tolerance has been conflicting(7,18,25,27).
Results from the present study indicate that while chronic sup-
plementation with EPA (1 g/kg body weight per d) or fish oil
(3 g/kg body weight per d) for more than 8 months lowers cir-
culating lipids (TAG, NEFA and cholesterol), neither treat-
ment delays the onset of diabetes in UCD-T2DM rats.
Similar to previous results from studies in animals and in
human subjects, energy intake, body weight and circulating
leptin were not affected by EPA or fish oil supplemen-
tation(4,6,23,27,34 – 36). In some rodent studies, decreases in
body weight have been reported during EPA and fish oil
treatment, which the authors attributed, in part, to increases
in circulating leptin(5,11). However, these results have not
been replicated in a number of other studies in rodents or
human subjects(4,6,23,27,34 – 36).
Neither EPA nor fish oil supplementation affected fasting
plasma glucose or insulin concentrations, suggesting that
these supplements did not affect insulin sensitivity in the
UCD-T2DM rat model of diabetes. These findings are in
agreement with previous studies in rodents(23,36) and several
clinical studies in patients with T2DM, in which no improve-
ments of glycaemic control, circulating insulin or insulin sen-
sitivity were observed during treatment with fish oil(25,37). In
some clinical studies, insulin sensitivity and glycaemic control
actually worsened during fish oil treatment, despite marked
improvements in circulating lipids(7,38 – 40). One possible
explanation for a lack of improvement of glycaemic control
with EPA or fish oil supplementation is that EPA and fish
oil may increase hepatic glucose output by increasing hepatic
free fatty acid oxidation and decreasing hepatic glucose
oxidation, as would be predicted by changes in the Randle
glucose–fatty acid cycle(41). This is supported by the data
generated by Holness et al.(23), reporting decreased insulin-
mediated suppression of endogenous glucose production and
impaired glucose-stimulated insulin secretion in animals fed
a diet supplemented with EPA and DHA. Furthermore,
Mostad et al.(27) reported decreased glucose utilisation,
measured with euglycaemic clamps, in patients with T2DM
supplemented with fish oil.
Both EPA and fish oil supplementation substantially
lowered circulating lipids in prediabetic and diabetic animals.
n-3 Fatty acids have been suggested to lower circulating lipids
by their interactions with several nuclear receptors, including
the liver X receptor, hepatocyte nuclear factor-4a, farnesol X
receptor and the PPAR(8). n-3 Fatty acids have been shown to
decrease de novo lipogenesis through inhibition of sterol-
regulatory-element-binding protein-1c(42) and to increase
fatty acid oxidation in liver and muscle through activation
of PPAR-a(43,44) and by down-regulating hepatocyte nuclear
factor-4a, resulting in a increased flux of glucose to
glycogen(45). Together, these effects favour fatty acid
oxidation over fatty acid storage as TAG. Interestingly, it
appeared that fish oil more potently lowered circulating
TAG than did EPA in prediabetic animals. The differential
effect of EPA and fish oil treatment on circulating lipids in
UCD-T2DM rats is supported by the previous studies in
which the TAG-lowering effect of DHA (present in fish oil)
was reported to be greater than that of EPA in healthy and
hyperlipidaemic men(6,18). The transient nature of the
decreases in circulating NEFA and TAG with EPA and fish
oil treatment can be attributed to increasing diabetes incidence
at older ages, as we have previously reported that fasting
plasma TAG decreases and fasting plasma NEFA increases
after diabetes onset in the UCD-T2DM rat(28).
Fatty acids in fish oil, such as EPA and DHA, have been
shown to activate PPAR-g resulting in increased adiponectin
production and secretion(20). Adiponectin is secreted from
adipocytes and promotes insulin sensitivity, in part, by stimulat-
ing the oxidation of ectopic TAG via activation of adenosine
monophosphate-activated protein kinase in liver and skeletal
muscle(19,46). However, we did not observe a significant
Table 2. Plasma C-reactive protein concentrations
(Mean values with their standard errors)
1 month (nmol/l) 4 months (nmol/l)
Mean SEM Mean SEM n
Control 295 42 604 91 19
EPA 228 20 560 60 15
Fish oil 231 23 527 57 16
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Fig. 5. Fasting plasma adiponectin (a) and leptin (b) concentrations in control
(n 19), EPA-supplemented (n 15) and fish oil (FO)-supplemented (n 16) ani-
mals. –W–, Control; –X–, EPA; K, FO.
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increase in circulating adiponectin concentrations during EPA
or fish oil supplementation, similar to previous human
studies(47,48). Thus, increased adiponectin production does
not appear to contribute to the lipid-lowering effects of EPA
and fish oil treatment observed in the present study.
While plasma CRP concentrations were slightly
(approximately 8–12 %) lower in EPA-supplemented and
fish oil-supplemented animals, this trend did not reach signi-
ficance, suggesting that EPA and fish oil do not effectively
reduce inflammation in UCD-T2DM rats, or that higher
doses may be required. Interestingly, there have been conflict-
ing reports on the effect of EPA or fish oil treatment
on markers of inflammation in individuals with diabetes,
suggesting that the effects of these supplements to reduce
inflammation may be at least partially dependent on metabolic
status and thus requires further investigation(3,4,49). This lack
of an anti-inflammatory effect may also, in part, explain the
lack of effect of EPA or fish oil supplementation to delay
diabetes onset, as inflammation is known to promote the
development of insulin resistance and diabetes(16,17).
Despite the widespread use of both fish oil and EPA sup-
plements, this is the first study to investigate the potential
for EPA and fish oil to delay or prevent the development of
T2DM in the UCD-T2DM rat model of type 2 diabetes. The
data indicate that EPA and fish oil supplementation do not
delay diabetes onset, nor do they affect body weight, plasma
glucose or insulin concentrations. Thus, these results do not
provide evidence to support the use of EPA and fish oil for
the prevention of T2DM. However, the results do confirm
that EPA and fish oil are useful in the management of hyper-
lipidaemia, a common co-morbidity of T2DM.
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